Warren, New Jersey, July 28, 2025 (Glove Newswire) – Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (NASDAQ: TVGN), today welcomes the release of the White House “Race: America's Action Plan.” The Centre for Excellence (and the National Institute of Standards) and the convening of stakeholders, led by the National Institute of Standards, builds the trust, governance and productivity of healthcare AI.
Together with AI Action Plan healthcare priorities, Tevogen.ai recently developed an Alpha version of ProjectCell™, a unique machine learning model built in collaboration with Microsoft (NASDAQ: MSFT) and DataBricks. This model could reduce targeted analysis in immunotherapy research for weeks and save billions of dollars in drug development costs. This approach reflects the action plan call for rapid scientific innovation and improved adoption of AI technology in the healthcare sector.
“As a mission-driven innovator, Tevogen.ai believes that AI can significantly reduce the costs and time required to bring life-saving treatment to patients in need,” said Tevogen founder and CEO, MD, MD, MD, MD, MD, MD and CEO. “We recognize this possibility and praise the US government for setting up a national strategy. With a focus on both innovation and equity, our work at Tevogen.AI seeks scalable and ethical solutions that expand access to affordable, advanced treatments for all Americans.”
A positive statement
This press release contains certain forward-looking statements relating to: Expectations for future growth. Expectations for the healthcare and biopharmaceutical industries. and the potential benefits, potential benefits, potential benefits, patient development, and patient access of product candidates for the treatment of infectious diseases and cancer. Forward-looking statements may be identified by words such as “May,” “can,” “can,” “expect,” “expect,” “possibility,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions. These statements are based on management expectations, assumptions, estimates, forecasts and beliefs as of the date of this press release and include known unknown risks, delays, uncertainties, and other factors that are not under the control of the Company, actual outcomes, performance, or performance expressed by these forward locksizements, or many other factors that may differ from other expectations.
Factors that may cause actual results, performance or results will differ from those expressed or implied by forward-looking statements. Changes in the markets where Tebong competes, including those relating to competitive landscapes, technological evolution, or regulations. Changes in general economic conditions both domestically and globally. The risk that Tevogen may not be able to implement its growth strategy or may experience difficulties in managing its growth and expanding operations. The risk that Tevogen may not be able to develop and maintain effective internal controls. To achieve Tevogen's commercialization and development plans and to identify and realize additional opportunities. This could be particularly affected by competition and affect Taebon's ability to grow and manage economically, employ and retain key employees. The risk that Tevogen may not be able to respond to rapid technical developments to provide new and innovative products and services, or the investment of large amounts of money in new products and services that have failed. Risks related to the ability to develop, license or obtain new treatments. Risks of regulatory litigation or litigation related to Taebon's business. Uncertainties inherent in the execution, cost, and completion of preclinical research and clinical trials. Risks related to regulatory review, approval, and commercial development. Risks related to intellectual property protection. Tevogen's restricted business history. These factors also discussed or incorporated by reference in Tebong's Annual Report on Form 10-K.
You should not undue reliance on forward-looking statements. Tevogen has no obligation to update forward-looking statements except as required by applicable law.
contact address
Tevogen Bio Communications
T: 1 877 Tevogen, Ext 701
communications@tevogen.com
